Phase I Study to Evaluate the Safety and Efficacy of MF101 as Well as the Pharmacokinetics of Its Key Active Components
NCT00453297
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
MF101
Sponsor
Bionovo